Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab prevention study in women with BRCA1 germline mutation
ISRCTN77394655Phase 3Active, not recruiting
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Denosumab with Placebo comparator (2 arms). Primary endpoints: Quality of life, Safety events after treatment and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN77394655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN77394655.